Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Completion of investment by Life Biosciences LLC and capital raising update

April 8, 2019 Kerry Rowe

Completion of investment by Life Biosciences LLC and capital raising update

Post navigation

Results of General Meeting

Change of Company Name

Related Posts

XBRL 30 June 2020 filed with the SEC

September 16, 2020September 16, 2020

Prana Completes Phase 2 Huntington Disease Trial with PBT2

October 6, 2013

New Publication Demonstrates ATH434 is Neuroprotective

July 15, 2021September 3, 2021

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065